Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second‐line treatment with tyrosine kinase inhibitor following first‐line immune‐oncology combination therapy
International Journal of Urology · 2024-05 · 31 (5) · 526-533
DOI: 10.1111/iju.15396 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, online erschienen am 19.01.2024. Verfasst von Yuto Matsushita und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Axitinib, Carcinoma, Renal Cell. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Objectives
This study aimed to assess the prognostic outcomes in mRCC patients receiving second‐line TKI following first‐line IO combination therapy.
Methods
This study retrospectively included 243 mRCC patients receiving second‐line TKI after first‐line IO combination therapy: nivolumab plus ipilimumab ( n = 189, IO–IO group) and either pembrolizumab plus axitinib or avelumab plus axitinib ( n = 54, IO–TKI group). Oncological outcomes between the two groups were compared, and prognostication systems were developed for these patients.
Results
In the IO–IO and IO–TKI groups, the objective response rates to second‐line TKI were 34.4% and 25.9% ( p = 0.26), the median PFS periods were 9.7 and 7.1 months ( p = 0.79), and the median OS periods after the introduction of second‐line TKI were 23.1 and 33.5 months ( p = 0.93), respectively. Among the several factors examined, non‐CCRCC, high CRP, and low albumin levels were identified as independent predictors of both poor PFS and OS by multivariate analyses. It was possible to precisely classify the patients into 3 risk groups regarding both PFS and OS according to the positive numbers of the independent prognostic factors. Furthermore, the c‐indices of this study were superior to those of previous systems as follows: 0.75, 0.64, and 0.61 for PFS prediction and 0.76, 0.70, and 0.65 for OS prediction by the present, IMDC, and MSKCC systems, respectively.
Conclusions
There were no significant differences in the prognostic outcomes after introducing second‐line TKI between the IO–IO and IO–TKI groups, and the histopathology, CRP and albumin levels had independent impacts on the prognosis in mRCC patients receiving second‐line TKI, irrespective of first‐line IO combination therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
- Department of Urology, Aichi Cancer Center, Nagoya, Aichi, Japan.
- Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Hokkaido, Japan.
- Department of Urology, Graduate School of Medicine and School of Medicine, Chiba University, Chiba, Chiba, Japan.
- Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
- Department of Urology, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Hiroshima, Japan.
ORCID-Profile: Yuto Matsushita, Takahiro Osawa, Tomokazu Sazuka, Shingo Hatakeyama, Keisuke Goto, Shuya Kandori, Kosuke Ueda, Hajime Tanaka, Yukari Bando, Takahiro Kimura, Shimpei Yamashita
Zitieren
APA
Matsushita, Y., Kojima, T., Osawa, T., Sazuka, T., Hatakeyama, S., Goto, K., Numakura, K., Yamana, K., Kandori, S., Fujita, K., Ueda, K., Tanaka, H., Tomida, R., Kurahashi, T., Bando, Y., Nishiyama, N., Kimura, T., Yamashita, S., Kitamura, H., …, & Japanese Urological Oncology Group (2024). Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second‐line treatment with tyrosine kinase inhibitor following first‐line immune‐oncology combination therapy. International Journal of Urology, 31(5), 526-533. https://doi.org/10.1111/iju.15396
Vancouver
Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, et al. Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second‐line treatment with tyrosine kinase inhibitor following first‐line immune‐oncology combination therapy. International Journal of Urology. 2024;31(5):526-533. doi:10.1111/iju.15396
BibTeX
@article{Matsushita2024,
author = {Matsushita, Yuto and Kojima, Takahiro and Osawa, Takahiro and Sazuka, Tomokazu and Hatakeyama, Shingo and Goto, Keisuke and Numakura, Kazuyuki and Yamana, Kazutoshi and Kandori, Shuya and Fujita, Kazutoshi and Ueda, Kosuke and Tanaka, Hajime and Tomida, Ryotaro and Kurahashi, Toshifumi and Bando, Yukari and Nishiyama, Naotaka and Kimura, Takahiro and Yamashita, Shimpei and Kitamura, Hiroshi and Miyake, Hideaki and Japanese Urological Oncology Group, Japanese Urological Oncology Group},
title = {Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second‐line treatment with tyrosine kinase inhibitor following first‐line immune‐oncology combination therapy},
journal = {International Journal of Urology},
year = {2024},
volume = {31},
number = {5},
pages = {526--533},
doi = {10.1111/iju.15396}
}
EUVIMED